Centre To Amend MDR To Include QMS Requirements For Certain Medical Devices

New Delhi:  The Central drug regulator may look at amending the Medical Device Rules (MDR), 2017 to include the Quality Management System (QMS) requirements for Class A non-sterile and non-measuring medical device, in order to ensure quality of these products.

The Drugs Technical Advisory Board (DTAB) in a recent meeting, has agreed with a proposal to amend the relevant sections of the Rules, which would mean an amendment in the Chapter IIIB, which was incorporated into the Rules through a notification in October, 2022.

The Board, in its 91st meeting held in August, was apprised that the MDR under Chapter III B specify the provisions for exemption of license to manufacture & import of the Class A (non-sterile and non-measuring) medical devices for marketing in the country.

While the Rule exempted licensing, the manufacturer or importer may obtain registration number by submitting the requisite information prescribed under sub-rule (2) of Rule 19H and sub-rule (2) of 19J of MDR, 2017, respectively.

It observed that the scope for conformance of QMS for manufacturing of such medical devices is not included in the rules. QMS is utmost important for manufacturing of medical devices to ensure that the product meets relevant standards and essential principles applicable for medical devices and the firm shall adhere with the QMS of fifth schedule of MDR, 2017, so that the safety and performance of medical devices will be ensured.

Hence, the undertaking stating that the manufacturing facility has complied the QMS as prescribed in the Fifth Schedule of MDR, 2017 may be included in the said rules, noted the Board.

“Accordingly, it was proposed that to amend rule 19H and 19J of Chapter IIIB of Medical Device Rules, 2017 to include the Quality Management System requirements for Class A (non-sterile and non-measuring) medical device,” said the DTAB.

The Board deliberated the matter and agreed for the proposed amendment under MDR, 2017, it said.

It may be noted that the Centre has notified the amendment of MDR, 2017, to exempt Class A (non-sterile and non-measuring) medical devices from import license and include the Chapter IIIB regarding the registration of these class of medical devices, in October, 2022. The Section 19H deals with information for registration to be uploaded by the industry, while 19J deals with the import of these class A medical devices.

The non-sterile and non-measuring medical devices include items such as gauze, instruments, scalpels, scissors, knives, etc.

Related Posts

Restricted pills in car lead to shadow pharmacy empire stretching from Kanpur to Ludhiana.

Ludhiana: A local tip-off has cracked open a Punjab-UP pipeline where a failed pharmacist allegedly turned a licensed shop into a launchpad for seven lakh banned tablets — dragging hardware…

Gang which supplied Rs100 cr codeine cough syrup busted

Varanasi:  In a major operation, the Uttar Pradesh Food Safety and Drug Administration (UPFSDA) and police have busted one of the biggest rackets of codeine-based cough syrup, used as an…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Restricted pills in car lead to shadow pharmacy empire stretching from Kanpur to Ludhiana.

Restricted pills in car lead to shadow pharmacy empire stretching from Kanpur to Ludhiana.

Gang which supplied Rs100 cr codeine cough syrup busted

Gang which supplied Rs100 cr codeine cough syrup busted

Mahima Choudhary was ‘Lucky’ Cancer lurking behind her ‘Choli’ was caught early

Mahima Choudhary was ‘Lucky’ Cancer lurking behind her ‘Choli’ was caught early

Ujjain Set to Become Medical Device Manufacturing Hub: 11 Major Firms Pledge ₹600 Crore Investment, 1,700+ Jobs

Ujjain Set to Become Medical Device Manufacturing Hub: 11 Major Firms Pledge ₹600 Crore Investment, 1,700+ Jobs

Zydus Lifesciences gets USFDA nod for Leuprolide Acetate injection

Zydus Lifesciences gets USFDA nod for Leuprolide Acetate injection

Lupin launches generic injection in US with 180-day exclusivity

Lupin launches generic injection in US with 180-day exclusivity